Department of Nutrition, School of Public Health, Guangdong Medical University, Zhanjiang, Guangdong, China.
Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Guangdong, China.
Expert Rev Gastroenterol Hepatol. 2022 Jun;16(6):537-545. doi: 10.1080/17474124.2022.2083605. Epub 2022 Jun 6.
Previous studies have demonstrated that ursodeoxycholic acid (UDCA) possesses anti-inflammatory, antioxidant, and anti-fibrotic properties, and it may reduce the degree of liver damage caused by nonalcoholic steatohepatitis (NASH). However, the effectiveness of UDCA in improving liver function and histology in cases of NASH remains unclear. Therefore, we performed a meta-analysis to assess the efficacy of UDCA in the treatment of NASH.
PubMed, Web of Science, Embase, Cochrane, and other databases were searched for randomized controlled trials (RCTs) published before 1 January 2022, in which UDCA was used to treat patients with NASH.
A total of 8 studies with 655 participantsmet the criteria for inclusion in this meta-analysis. The forest plot displayed that UDCA treatment significantly reduced blood concentrations of alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT). However, the pooled effect size results did not suggest any significant effect of UDCA on anthropometric characteristics or hepatic histology.
UDCA therapy can effectively reduce serum levels of ALT and GGT in patients with NASH but has no significant effects on physical characteristics or liver histology. Further large-scale and dose-response clinical studies are needed to evaluate the clinical potential of UDCA in treating NASH.
先前的研究表明，熊去氧胆酸（UDCA）具有抗炎、抗氧化和抗纤维化特性，它可能减轻非酒精性脂肪性肝炎（NASH）引起的肝损伤程度。然而，UDCA 改善 NASH 患者肝功能和组织学的效果尚不清楚。因此，我们进行了一项荟萃分析，以评估 UDCA 治疗 NASH 的疗效。
检索了 PubMed、Web of Science、Embase、Cochrane 及其他数据库，纳入了截至 2022 年 1 月 1 日之前发表的 UDCA 治疗 NASH 的随机对照试验（RCT）。
共有 8 项研究 655 名患者符合纳入标准。森林图显示，UDCA 治疗可显著降低 NASH 患者的丙氨酸氨基转移酶（ALT）和γ-谷氨酰转移酶（GGT）血浓度。然而，汇总效应量结果并未表明 UDCA 对人体测量特征或肝组织学有显著影响。
UDCA 疗法可有效降低 NASH 患者的血清 ALT 和 GGT 水平，但对身体特征或肝组织学无显著影响。需要进一步的大规模、剂量反应临床研究来评估 UDCA 治疗 NASH 的临床潜力。
